Quantisnow Logo
Dashboard

AngioDynamics to Report Fiscal 2024 Fourth Quarter and Full-Year Financial Results on July 16, 2024

$ANGO
Medical/Dental Instruments
Health Care
Get the next $ANGO alert in real time by email

AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the fourth quarter and fiscal year 2024 before the market open on Tuesday, July 16, 2024. The Company's management will host a conference call at 8:00 a.m. ET the same day to discuss the results.

To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international).

This conference call will also be webcast and can be accessed from the "Investors" section of the AngioDynamics website at investors.angiodynamics.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

A recording of the call will also be available, until Tuesday, July 23, 2024 at 11:59 PM ET. To hear this recording, dial 1-844-512-2921 (domestic) or +1-412-317-6671 (international) and enter the passcode 13747424.

About AngioDynamics, Inc.

AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients.

The Company's innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visit www.angiodynamics.com.

Get the next $ANGO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ANGO

DatePrice TargetRatingAnalyst
4/5/2024$12.00Perform → Outperform
Oppenheimer
9/25/2023$19.00Buy
H.C. Wainwright
4/17/2023$14.00 → $13.00Strong Buy → Outperform
Raymond James
10/15/2021$28.00 → $37.00Hold → Buy
Canaccord Genuity
8/20/2021Perform
Oppenheimer
7/14/2021$24.00 → $28.00Hold
Canaccord Genuity
7/9/2021$27.00 → $32.00Strong Buy
Raymond James
More analyst ratings

$ANGO
 Press Releases

Fastest customizable press release news feed in the world

See more

  • AngioDynamics to Host Virtual Cardiovascular Investor Event

    AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, will host a virtual cardiovascular investor event this Wednesday, April 2, 2025 at 9:00am ET. The event will take place immediately following the Company's Fiscal 2025 Third Quarter Financial Results Conference Call which will start at 8:00am ET the same day. Virtual Cardiovascular Investor Event Date: Wednesday, April 2, 2025 Time: 9:00am ET Duration: 60 minutes Webcast Registration Link: https://viavid.webcasts.com/starthere.jsp?ei=1712212&tp_key=c

    $ANGO
    Medical/Dental Instruments
    Health Care

  • AngioDynamics to Report Fiscal 2025 Third Quarter Financial Results on April 2, 2025 and Host Virtual Cardiovascular Investor Event

    AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the third quarter of fiscal year 2025 before the market open on Wednesday, April 2, 2025, followed by a virtual cardiovascular investor event, offering a deeper dive into the company's cardiovascular business and products. Fiscal 2025 Third Quarter Financial Results Conference Call The Company's management will host a conference call at 8:00 am ET the same day to discuss the results. To participate

    $ANGO
    Medical/Dental Instruments
    Health Care

  • AngioDynamics to Present at the Oppenheimer 35th Annual Healthcare MedTech and Services Virtual Conference

    AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the Oppenheimer 35th Annual Healthcare MedTech and Services Virtual Conference at 12:00 p.m. ET on Monday, March 17, 2025. A live webcast of the presentation will be accessible through the "Investors" section of the Company's website at www.angiodynamics.com and will be available for repl

    $ANGO
    Medical/Dental Instruments
    Health Care

$ANGO
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ANGO
 Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$ANGO
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ANGO
 SEC Filings

See more

$ANGO
 Leadership Updates

Live Leadership Updates

See more

  • AngioDynamics Announces Addition of Lorinda Burgess to Board of Directors

    AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced the appointment of Lorinda Burgess to the Company's Board of Directors. Ms. Burgess brings over 35 years of management, financial, and global operations experience, including over 15 years at Medtronic, Inc., where she was responsible for the company's Americas Region as CFO, Vice President of Finance. While at Medtronic, Ms. Burgess led optimization initiatives that drove operational efficiencies and significant cost reductions. "Ms

    $ANGO
    Medical/Dental Instruments
    Health Care

  • PAVmed Appoints Shaun O'Neil as Chief Operating Officer

    PAVmed Inc. (NASDAQ:PAVM, PAVMZ))) (the "Company" or "PAVmed"), a diversified commercial-stage medical technology company and parent of cancer prevention company Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid"), today announced the appointment of Shaun O'Neil to serve as Executive Vice President and Chief Operating Officer, overseeing diverse corporate operations and commercial activities across the Company and its subsidiaries. Mr. O'Neil has served as PAVmed's Chief Commercial Officer and Executive Vice President, Business Development since joining the Company in 2018. He will serve on the Company's Executive Committee and as an executive officer pursuant to Section 16(a) of the Securities

    $ANGO
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

  • AVITA Medical, Inc. Appoints Two New Non-Executive Members to the Board of Directors

    VALENCIA, Calif. and MELBOURNE, Australia, June 01, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))) ("AVITA Medical"), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today the appointment of James Corbett and Jan Stern Reed to its Board of Directors effective July 1, 2021. Mr. Corbett has approximately 40 years of leadership experience in the medical device field, most recently, as CEO of CathWorks Ltd., a software-based medical technology company. Mr. Corbett has extensive global commercial and operating experience, serving as an

    $SCL
    $RCEL
    $ANGO
    Package Goods/Cosmetics
    Consumer Discretionary
    Medical/Dental Instruments
    Health Care

$ANGO
 Financials

Live finance-specific insights

See more

  • AngioDynamics to Host Virtual Cardiovascular Investor Event

    AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, will host a virtual cardiovascular investor event this Wednesday, April 2, 2025 at 9:00am ET. The event will take place immediately following the Company's Fiscal 2025 Third Quarter Financial Results Conference Call which will start at 8:00am ET the same day. Virtual Cardiovascular Investor Event Date: Wednesday, April 2, 2025 Time: 9:00am ET Duration: 60 minutes Webcast Registration Link: https://viavid.webcasts.com/starthere.jsp?ei=1712212&tp_key=c

    $ANGO
    Medical/Dental Instruments
    Health Care

  • AngioDynamics to Report Fiscal 2025 Third Quarter Financial Results on April 2, 2025 and Host Virtual Cardiovascular Investor Event

    AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the third quarter of fiscal year 2025 before the market open on Wednesday, April 2, 2025, followed by a virtual cardiovascular investor event, offering a deeper dive into the company's cardiovascular business and products. Fiscal 2025 Third Quarter Financial Results Conference Call The Company's management will host a conference call at 8:00 am ET the same day to discuss the results. To participate

    $ANGO
    Medical/Dental Instruments
    Health Care

  • AngioDynamics Reports Fiscal Year 2025 Second Quarter Financial Results

    AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the second quarter of fiscal year 2025, which ended November 30, 2024. Fiscal Year 2025 Second Quarter Highlights   Quarter Ended November 30, 2024 Pro Forma* YoY Growth Pro Forma* Net Sales $73.0 million 9.2% Med Tech Net Sales $31.5 million 25.0% Med Device Net Sales $41.5 million (0.4)% GAAP Gross margin of 54.8% GAAP loss pe

    $ANGO
    Medical/Dental Instruments
    Health Care

$ANGO
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more